Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti
ScripUS/Swiss biotech GlycoEra AG announced a $130m series B financing on 27 May that it says will enable it to advance its first protein-degradation drug candidate through Phase II proof of concept as pre
ScripTherapies ranging from small molecules to immuno-oncology drugs will make appearances at the 2025 American Society of Clinical Oncology meeting. These include drugs that are seen as having the potenti
In VivoAt SynBioBeta 2025, In Vivo spoke with several executives leading companies at the cutting edge of synthetic biology and techbio. These conversations revealed not just technological breakthroughs, b